Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
OwnerDaria Onichtchoukinventor
Life of this patent
Estimating the term…
Abstract
The present invention discloses proteins secreted by the developing pancreas, and polynucleotides, which identify and encode the proteins. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g diabetes), obesity, and/or metabolic syndrome.
Claims23
1-36. (canceled)
A pharmaceutical composition comprising a DG008, DG065, DG210, or DG239 protein and/or a functional fragment thereof, a nucleic acid molecule encoding a DG008, DG065, DG210, or DG239 protein and/or a functional fragment thereof and/or an effector/modulator of said nucleic acid molecule and/or said protein or protein fragment, wherein the composition optionally contains pharmaceutically acceptable carriers, diluents, and/or additives.
Use of a DG008, DG065, DG210, or DG239 nucleic acid molecule or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide and/or an effector/modulator of said nucleic acid or polypeptide for the manufacture of a medicament for the treatment of pancreatic diseases (e.g. diabetes such as insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus), obesity, metabolic syndrome and/or other metabolic diseases or dysfunctions for controlling the function of a gene and/or a gene product which is influenced and/or modified by a DG008, DG065, DG210, or DG239 polypeptide.
Use of a DG008, DG065, DG210, or DG239 nucleic acid molecule or use of a polypeptide encoded thereby, or use of a fragment or a variant of said nucleic acid molecule or said polypeptide, or use of an effector/modulator of said nucleic acid molecule or said polypeptide for identifying substances capable of interacting with a DG008, DG065, DG210, or DG239 polypeptide in vitro and/or in vivo.
A non-human transgenic animal exhibiting a modified expression of a DG008, DG065, DG210, or DG239 polypeptide, particularly wherein the expression of the DG008, DG065, DG210, or DG239 polypeptide is increased and/or reduced.
A method of identifying a (poly)peptide involved in the regulation of energy homeostasis and/or metabolism in a mammal comprising the steps of
- a contacting a collection of (poly)peptides with a DG008, DG065, DG210, or DG239 homologous polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides;
- b removing (poly)peptides which do not bind and
- c identifying (poly)peptides that bind to said DG008, DG065, DG210, or DG239 homologous polypeptide.
A method of screening for an agent which effects/modulates the interaction of a DG008, DG065, DG210, or DG239 polypeptide with a binding target comprising the steps of
- a incubating a mixture comprising
- b a DG008, DG065, DG210, or DG239 polypeptide or a fragment thereof;
- c a binding target/agent of said DG008, DG065, DG210, or DG239 polypeptide or fragment thereof;
- and
- d a candidate agent under conditions whereby said polypeptide or fragment thereof specifically binds to said binding target at a reference affinity;
- e detecting the binding affinity of said DG008, DG065, DG210, or DG239 polypeptide or fragment thereof to said binding target to determine an affinity for the agent;
- and
- f determining a difference between affinity for the agent and reference affinity.
A method for screening for an agent, which effects/modulates the activity of a DG008, DG065, DG210, or DG239 polypeptide, comprising the steps of
- a incubating a mixture comprising
- b a DG008, DG065, DG210, or DG239 polypeptide or a fragment thereof;
- and
- c a candidate agent under conditions whereby said DG008, DG065, DG210, or DG239 polypeptide or fragment thereof exhibits a reference activity,
- b detecting the activity of said DG008, DG065, DG210, or DG239 polypeptide or fragment thereof to determine an activity for the agent;
- and
- c determining a difference between activity for the agent and reference activity.
Use of a DG008, DG065, DG210, or DG239 nucleic acid molecule or of a fragment thereof for the production of a non-human transgenic animal which over- or under-expresses the DG008, DG065, DG210, or DG239 gene product.
Kit comprising at least one of
- a a DG008, DG065, DG210, or DG239 nucleic acid molecule or a functional fragment or an isoform thereof;
- b a DG008, DG065, DG210, or DG239 amino acid molecule or a functional fragment or an isoform thereof;
- c a vector comprising the nucleic acid of (a);
- d a host cell comprising the nucleic acid of (a) or the vector of (c);
- e a polypeptide encoded by the nucleic acid of (a), expressed by the vector of (c) or the host cell of (a);
- f a fusion polypeptide encoded by the nucleic acid of (a);
- g an antibody, an aptamer or another effector/modulator against the nucleic acid of (a) or the polypeptide of (b), (e), or (f) and/or an anti-sense oligonucleotide of the nucleic acid of (a).
Dependencies are inferred from the claim text.